A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia

Clinical Infectious Diseases

Volumn 33, Issue 8, 2001, Pages 1295-1301

  Favero, Albano Del ^a   Menichetti, F ^b   Martino, Pietro ^c   Bucaneve, Giampaolo ^a   Micozzi, Alessandra ^c   Gentile, Giuseppe ^c   Furno, Paolo ^a   Russo, Domenico ^d   D'Antonio, Domenico ^c   Ricci, Paolo ^e   Martino, Bruno ^f   Mandelli, F ^c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b CISANELLO HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY HOSPITAL OF UDINE   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f Azienda Ospedaliera   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTINEOPLASTIC AGENT; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HODGKIN DISEASE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SOLID TUMOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AMIKACIN; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FEVER; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PENICILLANIC ACID; PIPERACILLIN; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0035887790     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/322646     Document Type: Article

References (15)

1. Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials
2. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
3. Significance of antimicrobial synergism for the outcome of gram-negative sepsis
4. Synergistic combinations of antibiotics in gram-negative bacillary infections
5. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia
6. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
7. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: A multicenter randomized trial
8. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients
9. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia
10. Piperacillin/tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
11. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients
12. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients
13. Traitement empirique des episodes febriles survenant chez les patients cancereux presentant une neutropenie prolongee: Essai comparatif ceftazidime seule, ceftazidime + amikacine et ceftazidime + vancomycine
14. Amikacin serum concentrations: Prediction of levels and dosage guidelines